MNOV · Company research
Medicinova, Inc. (MNOV): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| MNOV Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.05 per Share - Earnings Miss Streak - https://www.dars.gov.et/ | MNOV Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.05 per Share - Earnings Miss Streak https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 12, 2026 | neutral | 0 | 0.6 |
| Two cholesterol measures improved significantly, but the trial missed its primary endpoints. - Stock Titan | Two cholesterol measures improved significantly, but the trial missed its primary endpoints. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| MNOV Q2 2026 Earnings: Narrower-Than-Expected Loss Draws Muted Market Response - Low Estimate Range - https://www.dars.gov.et/ | MNOV Q2 2026 Earnings: Narrower-Than-Expected Loss Draws Muted Market Response - Low Estimate Range https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 8, 2026 | neutral | 0 | 0.6 |
| MediciNova to Participate in the Maxim Growth Summit | MediciNova announced that management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York to meet with investors. The company is developing late-stage clinical programs for inflammatory, fibrotic, and neurodegenerative diseases, with lead asset MN-166 (ibudilast) in trials for ALS, DCM, and MS, and MN-001 (tipelukast) being evaluated for IPF and NAFLD. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| MediciNova to Participate in the Maxim Growth Summit | MediciNova announced that management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York to meet with investors. The company is developing late-stage clinical programs for inflammatory, fibrotic, and neurodegenerative diseases, with lead asset MN-166 (ibudilast) in trials for ALS, DCM, and MS, and MN-001 (tipelukast) being evaluated for IPF and NAFLD. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Two holders sold 640,000 MediciNova (NASDAQ: MNOV) shares and still report an ownership stake. - Stock Titan | Two holders sold 640,000 MediciNova (NASDAQ: MNOV) shares and still report an ownership stake. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| MediciNova (NasdaqGM:MNOV) Stock Forecast & Analyst Predictions - Simply Wall Street | MediciNova (NasdaqGM:MNOV) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 29, 2026 | neutral | 0 | 0.6 |
| After a sale, an investment manager still reports 4.86 million MediciNova (MNOV) shares held indirectly. - Stock Titan | After a sale, an investment manager still reports 4.86 million MediciNova (MNOV) shares held indirectly. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV) - Benzinga | Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV) Benzinga | View source ↗ | Benzinga | Sep 28, 2026 | neutral | 0 | 0.6 |
| Medicinova (MNOV) Sinks 29.84% to $1.81 as Shares Test Lower Support - Fibonacci Retracement - www.dars.gov.et | Medicinova (MNOV) Sinks 29.84% to $1.81 as Shares Test Lower Support - Fibonacci Retracement www.dars.gov.et | View source ↗ | www.dars.gov.et | Sep 28, 2026 | neutral | 0 | 0.6 |
| A 40-person study found more “good” cholesterol with MediciNova's drug, but no significant liver-fat difference. - Stock Titan | A 40-person study found more “good” cholesterol with MediciNova's drug, but no significant liver-fat difference. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| The blinded phase of an ALS drug trial is complete. Results are expected by year-end. - Stock Titan | The blinded phase of an ALS drug trial is complete. Results are expected by year-end. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Biotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews | Biotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO RTTNews | View source ↗ | RTTNews | Sep 18, 2026 | neutral | 0 | 0.6 |
| Biotech Stocks At 52-Week Highs - MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12% - RTTNews | Biotech Stocks At 52-Week Highs - MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12% RTTNews | View source ↗ | RTTNews | Sep 16, 2026 | neutral | 0 | 0.6 |
| MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - Kalkine | MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates Kalkine | View source ↗ | Kalkine | Aug 15, 2026 | neutral | 0 | 0.6 |
| MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance | MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| MediciNova, Inc. (MNOV) stock price, news, quote and history - Yahoo Finance - Yahoo Finance Singapore | MediciNova, Inc. (MNOV) stock price, news, quote and history - Yahoo Finance Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Nov 2, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 9, 2024 | neutral | 0 | 0.6 |
| MediciNova, Inc. (MNOV) Stock Price, News, Quote & History - Yahoo! Finance Canada | MediciNova, Inc. (MNOV) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | May 9, 2017 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.